FDA has granted Fast Track designation for ACX-362E, an investigational new treatment for C diff that is being developed by Acurx Pharmaceuticals, LLC.
Health care providers in the US should be aware of an outbreak of an antibiotic-resistant strain of Pseudomonas aeruginosa at a Mexico hospital where US residents frequently undergo invasive medical procedures.
To explore the long-term outcomes of treatment for recurrent C diff, NIAID has launched a new trial that will follow patients for 4 years to assess the safety of fecal microbiota transplants.
Mutual of Omaha will no longer deny coverage to individuals using PrEP for HIV prevention following allegations of discrimination in 2 separate legal settlements.
